Cardiovascular disease is the world's biggest killer, with 17.9 million
people dying from cardiovascular disease each year, accounting for 31%
of all deaths each year. Coronary arteries are a group of blood vessels
that surround the heart like a network. These vessels carry oxygen and
nutrients to the tissues of the heart and ensure that the heart functions
properly. Coronary artery disease (CAD) is one of the most common causes
of death worldwide. Coronary artery plaque buildup can form atherosclerosis,
which causes blood vessels to narrow and harden. This reduces the flow
of blood to the heart, which in turn causes patients to experience a range
of symptoms, such as chest pain and cardiac arrest.
Depending on the extent, severity, and clinical presentation of CAD, available
treatments include medication, surgery, or a combination of both. Current
medications for CAD are routinely used to improve cardiac pumping, dilate
blood vessels, improve blood flow, slow the heart rate, lower blood pressure,
reduce the load on the heart, and reduce fluid retention.
Recombinant fibroblast growth factor-1
Fibroblast growth factor (FGF) 1 has a wide range of mitogenic and cell
survival activities and is involved in a variety of biological processes.
FGF1 has been noted as a potential new molecule in the prevention and treatment
of cardiovascular disease, mainly due to its metabolic and angiogenic effects.
A placebo-controlled, double-blind, dose-varying study of human recombinant
FGF-1 for the treatment of subjects with severe coronary artery disease
is currently underway.
Recombinant human basic fibroblast growth factor
Basic FGF (bFGF) transmits developmental signals and promotes mesodermal
and neuroectodermal cell division. Has a strong angiogenic effect. Many
studies have demonstrated the ability of bFGF to induce functionally significant
angiogenesis in several different animal models of myocardial ischemia.
In addition to this, studies have demonstrated that intracoronary administration
of recombinant bFGF appears to be safe and well-tolerated in the 100-fold
Complement activator blocker-2
Complement activation plays a functional role in the pathogenesis of the
cardiovascular disease (CVD). Complement activation blocker-2 (CAB-2) is
a recombinant soluble chimeric protein derived from human decay-accelerating
factor (DAF) and membrane cofactor proteins. It inhibits C3 and C5 convertases
of both the classical and alternative pathways. It has been used in the
use and treatment of coronary artery disease.
In the last decade, significant advances have been made in the treatment
of CAD. Collaborations between different scientific fields such as biotechnology
and tissue engineering have led to the development of novel therapeutic
strategies such as stem cells, nanotechnology, robotic surgery, and other
advances (3D printing and drugs.) Creative BioMart also sees greater potential in the therapeutic field of CAD. In addition
to providing our customers with recombinant protein products for research,
we are confident that we can provide you with the necessary technical support
to meet your needs for a comprehensive understanding of the latest research
areas and to accelerate your existing projects. Please feel free to
for the latest news or details on related products. We look forward to
working with you in the CAD field.